Clinical Trials
20 trialsNCT02298959 2026-05-13
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02159989 2025-10-20
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT00407654 2024-03-04
VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00437034 2021-02-08
Aflibercept for Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT02101918 2020-03-23
Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00462826 2019-07-23
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01258855 2019-05-10
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00436501 2019-02-26
VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00450255 2018-05-24
VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT02192541 2018-03-29
Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT00828139 2017-08-21
S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00357760 2017-06-23
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00729157 2017-03-15
Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00390234 2015-12-07
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00369590 2015-10-02
VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide
National Cancer Institute (NCI)
Phase 2 Completed
NCT00509249 2015-01-08
Aflibercept in Treating Patients With Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00407485 2014-10-20
VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium
National Cancer Institute (NCI)
Phase 2 Completed
NCT00650923 2014-05-30
Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00369655 2014-05-05
VEGF Trap in Treating Patients With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00622414 2014-02-24
Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed